Everolimus in Hepatocellular Carcinoma

Researchers continue to search for a molecular pathway or biomarker to improve treatment options for patients with sorafenib-refractory HCC.

Novel Combination for Refractory Metastatic CRC

Results of the RECOURSE trial may make the combination agent a new standard of care in advanced disease.

Collaborative Trials to Speed Drug Development

Lung-MAP and the National Lung Matrix Trial aim to deliver precision-based treatment to patients with lung cancer by using a streamlined trial design

Financial Toxicity of Cancer Care

Cancer care costs are becoming a significant problem; however, a new tool may help oncologists assess how patients will be affected by treatment expenses.

Different Name, Same Great Oncology Resource

Chemotherapy Advisor is changing its name to better reflect the changing landscape of cancer care.

Misdiagnosis of HER2-Negative Breast Cancer

Inaccurate test results falsely classify some women as HER2 negative, denying them the benefits of targeted treatment.

Featured Videos


Viewpoints & Feature Articles

Supreme Court Ruling Puts Gynecologic Cancer Prevention at Risk

Supreme Court Ruling Puts Gynecologic Cancer Prevention at Risk

SCOTUS decision in Hobby Lobby case reaches beyond contraception.

Collaborative Precision Medicine Lung Cancer Trials to Speed Drug Development

Collaborative Precision Medicine Lung Cancer Trials to Speed Drug Development

Lung-MAP and the National Lung Matrix Trial aim to deliver precision-based, FDA-approved treatment to patients with lung cancer by using a streamlined trial design that allows flexibility for the investigators, patients, and drug manufacturers.

'Truly Personalized Medicine' Emphasizes Value—Not Cost—of Cancer Care

'Truly Personalized Medicine' Emphasizes Value—Not Cost—of Cancer Care

With the cost of cancer care rising, an ASCO task force has been established to create a framework for assessing relative value of cancer treatment.

ASCO 2014: A Fellow's Take on Posters, Presentations, and the Magnificent Mile

ASCO 2014: A Fellow's Take on Posters, Presentations, and the Magnificent Mile

Muhammad Rizvi, MD, discusses lung cancer research from ASCO 2014.


Editorial Advisory Board

 

Barbara Ann Burtness, MD

Steven Cohen, MD

E. David Crawford, MD

Don S. Dizon, MD, FACP

Jeffrey M. Farma, MD

Edith A. Perez, MD

Neal D. Shore, MD, FACS

Mark A. Socinski, MD

Mario Sznol, MD

Click here for complete profiles


From Oncology Nurse Advisor

CTA Community Poll

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs